Overview


According to FutureWise analysis the market for immuno-oncology in 2023 is US$ 101.4 billion, and is expected to reach US$ 240 billion by 2031 at a CAGR of 12%.

Cancer immunotherapy, also known as immuno-oncology, is a way of treating cancer by employing the body's own immune system to stop, eliminate, and control the disease. By boosting your immune system, giving your body more components to boost the immunological response, and teaching your body to recognise and fight particular cancer cells, it can also aid in the elimination of cancer. In cancer immunotherapy, a number of therapies are available, such as targeted antibodies, cancer vaccines, adoptive cell transfer, tumour-infecting viruses, checkpoint inhibitors, cytokines, and adjuvants. Immunotherapies are a type of biotherapy (also known as biologic therapy or biological response modifier (BRM) therapy), which uses compounds from living organisms to treat disease.

The Department of Immuno-Oncology is at the forefront of medical research that uses the body's immune system to combat cancer. Due to its potential to utilise the body's built-in immunity to infection, immunotherapy is a significant tool against cancer. T-cell treatment, which employs specialised immune system cells to target and eliminate cancer cells, and immune checkpoint blockade, which modifies or strengthens the immune system to attack and eradicate tumour cells, are two cancer immunotherapies now in use. For some people with metastatic cancer, these treatments work. But, researchers in the Department of Immuno-Oncology envision immunotherapy playing a much more significant role in the fight against cancer. By making immunotherapy a very effective first-line treatment option that can result in more potent, less toxic treatments, scientists hope to advance immunotherapy to the front lines. In order to treat patients with early-stage cancer and remove the microscopic residual disease that might cause cancer to return even after chemotherapy, radiation therapy, and surgery have been successful, researchers are aiming to further improve the effectiveness of these innovative medicines.

FutureWise Market Research has published a report that provides an insightful analysis of Immuno-oncology market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the Immuno-oncology market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb
  • MerckCo., Inc.
  • Novartis
  • AstraZeneca Plc
  • Pfizer Inc
  • Eli Lilly and Company
  • Johnson And Johnson
  • Amgen Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The market for immuno-oncology drugs is projected to expand as a result of the increase in cancer diagnoses worldwide. Lung, prostate, bowel, and female breast cancer account for 43% of all new instances of cancer, making them the four most prevalent cancers worldwide. Therefore, it is projected that over the next few years, demand for immuno-oncology medications would increase due to the rise in cancer incidence rates around the world. One major problem hindering the market's expansion is the high price of immuno-oncology treatments. People who require immunotherapy for cancer frequently cannot afford it since the immunotherapy treatments are more expensive than conventional cancer medications.  As a result, it is anticipated that the market for immuno-oncology drugs will experience slow growth due to the high cost of immuno-oncology therapy. Strategic partnerships are helping businesses in the immuno-oncology medicine sector increase the innovation of their products. Companies are creating breakthrough medicines and exchanging knowledge and resources with other businesses in order to survive in the fiercely competitive immuno-oncology drug industry. Companies have worked with academic and research institutions in this sector for a long time through partnerships and in- or out-licensing agreements, but in recent years this trend has become more prevalent. AI offers innovative and effective ways to evaluate various immune characteristics. The success of cancer immunotherapy can be directly correlated with a range of immune-associated signals that can be detected and measured using AI-based technologies. Therefore, there has been a surge in the use of AI in the field of immunotherapy, which can help to advance the therapy and accelerate market growth.

By Product Class

  • Monoclonal Antibodies
    • Naked Monoclonal Antibodies
      • Rituxan (Rituximab)
      • Avastin (Bevacizumab)
      • Herceptin (Trastuzumab)
    • Conjugated Monoclonal Antibodies
      • ADCETRIS (Brentuximab vedotin)
      • Kadcyla (Ado-trastuzumab emtansine/TDM-1)
    • Bispecific Monoclonal Antibodies
      • Blincyto (Blinatumomab)
    • Others
  • Therapeutic Vaccines
    • Provenge
  • Immune Checkpoint Inhibitors
    • CTLA-4 Inhibitors (Cytotoxic T-lymphocyte-associated Protein-4)
      • Yervoy (Ipilimumab)
    • PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand)
      • Opdivo (Nivolumab)
      • Keytruda (Pembrolizumab)
  • Others

By Major Indications

  • Head And Neck Cancer
  • Lung Cancer
  • Melanoma
  • Lymphoma
  • Leukemia
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. North America is a significant market for immune-oncology therapies due to rising cancer rates and growing knowledge of such therapy options. North American cancer patients are more likely to choose cutting-edge treatments like immunotherapy, which eventually increases the need for facilities for such therapies in this region. Due to the rising demand for immunotherapies and medications or treatments among middle-aged and older people in this area, the North American market holds the largest position in the global immuno-oncology market throughout the course of the forecast year. Moreover, based on product type segment, targeted antibody holds majority market share of 32.1%, followed by cancer vaccine at 6.5% in the global market in 2022.


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Immuno-Oncology Market By Product Class, By Major Indications and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to:sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Immuno-Oncology Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Immuno-Oncology Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Immuno-Oncology Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Immuno-Oncology Market, By Product Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Monoclonal Antibodies
         1.1. Naked Monoclonal Antibodies
          1.1.1. Rituxan (Rituximab)
          1.1.2. Avastin (Bevacizumab)
          1.1.3. Herceptin (Trastuzumab)
         1.2. Conjugated Monoclonal Antibodies
          1.2.1. ADCETRIS (Brentuximab vedotin)
          1.2.2. Kadcyla (Ado-trastuzumab emtansine/TDM-1)
         1.3. Bispecific Monoclonal Antibodies
          1.3.1. Blincyto (Blinatumomab)
         1.4. Others
        2. Therapeutic Vaccines
         2.1. Provenge
        3. Immune Checkpoint Inhibitors
         3.1. CTLA-4 Inhibitors (Cytotoxic T-lymphocyte-associated Protein-4)
          3.1.1. Yervoy (Ipilimumab)
         3.2. PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand)
          3.2.1. Opdivo (Nivolumab)
          3.2.2. Keytruda (Pembrolizumab)
        4. Others

  • 8.   Immuno-Oncology Market, By Major Indications Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Head And Neck Cancer
        2. Lung Cancer
        3. Melanoma
        4. Lymphoma
        5. Leukemia
        6. Others

  • 9.   North America Immuno-Oncology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Immuno-Oncology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Immuno-Oncology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Immuno-Oncology Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F. Hoffmann-La Roche AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bristol-Myers Squibb
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. MerckCo., Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Novartis
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. AstraZeneca Plc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Eli Lilly and Company
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Johnson And Johnson
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Amgen Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

FAQ


The current size of the Immuno-Oncology market is substantial and continues to grow at a notable rate. Projections suggest significant expansion due to advancements in research, higher investment in healthcare, and an increasing number of cancer cases worldwide. For precise figures and detailed projections, please refer to our latest market research reports.

Key factors fueling the growth of the Immuno-Oncology market include:

  • The rise in global cancer incidents and prevalence.
  • Breakthroughs in Immuno-Oncology therapy and treatments.
  • Increasing healthcare expenditure and robust investment in research and development by pharmaceutical companies.
  • Growing awareness and acceptance of personalized medicine and therapies.
  • Supportive government policies and funding for cancer research.

The Immuno-Oncology market is a global entity with regional variations due to factors like healthcare infrastructure, regulatory environments, and economic conditions. Currently, North America and Europe are leading in market share. However, Asia-Pacific regions are expected to show promising growth due to improving healthcare systems and rising investments in health technology.

The Immuno-Oncology market faces several challenges such as:

  • High costs associated with therapy and research.
  • Complexities in regulatory compliance and approval processes.
  • Intellectual property rights issues and market competition.
  • Operational challenges in clinical trials.
  • Need for improved predictive biomarkers and testing methodologies.

Healthcare providers can stay informed by attending medical conferences, participating in continued medical education (CME), subscribing to relevant medical journals, joining professional communities, and collaborating with researchers. Pharmaceutical companies and research organizations also frequently provide updates on the latest findings and advancements.

Recent advancements in immuno-oncology research include the development of checkpoint inhibitors, chimeric antigen receptor T-cell therapies, and cancer vaccines. These treatments have been significant because they offer new ways to treat cancer that could be more effective or have fewer side effects compared to older therapies, and they extend the range of cancers that can be treated using immunotherapy.

Related Market

Immuno Oncology Drugs Market

Read More

Immunostimulatory Adjuvants Market

Read More

Angioimmunoblastic T-Cell Lymphoma Market

Read More

Immunodermatology Market

Read More

Immunochemistry Reagents Market

Read More
Partner

Our Clients